NEW YORK (GenomeWeb News) – Metabolon announced today that it is collaborating with Harvard-Partners Center for Genetics and Genomics on developing a new test for warfarin dosing.
 
The alliance is aimed at determining whether a patient’s metabolomic profile will increase the likelihood of correctly dosing wafarin.
 
HPCGG is a joint effort between Harvard Medical School and Partners Healthcare medical system in the Boston area.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.